This study examined the effect of icosapent ethyl (IPE; Vascepa) on major cardiovascular events (MACEs) in statin-treated patients that had previous heart attacks (myocardial infarction; MI). The data showed that patients treated with IPE had large and significant reductions in MACEs.

This analysis investigated the relationship between anti-diabetic medications and the risk of fractures in patients with type 2 diabetes (T2D). The data showed that glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sulfonylurea (SU) provided better protection against fractures compared to thiazolidinedione (TZD) or dipeptidyl peptidase-4 inhibitors (DPP-4is) while sodium-glucose cotransporter-2 inhibitors (SGLT-2i) increased the risk of fractures compared to GLP1-RAs.

This study compared the effectiveness and safety of an early and a delayed invasive strategy (IS) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS). The data showed that there were no significant differences in the risk of death, heart attacks, stroke rates, major bleeding, or revascularization between early and delayed IS. Early IS significantly reduced the risk of recurrent ischemia and length of hospital stay in these patients.

This study analyzed the long-term effect of behavioral counseling on increasing daily physical activity (PA) and reducing sedentary (SED) time on changes in beta-cell (β-cell) function and glucose control in patients with type 2 diabetes (T2D). The authors concluded that increasing moderate-to-vigorous-intensity physical activity (MVPA) and reducing SED time can effectively preserve the β-cell function of the pancreas and improve glucose control in these patients.

This study compared the effectiveness and safety between biodegradable polymer (BP) drug-eluting stents (DES) and durable polymer (DP) DESs in patients with acute coronary syndrome (ACS). The data showed that both stent types demonstrated excellent effectiveness and safety after 1 year. The authors suggested that BP-DES may be more favorable when treating patients with ACS as there was a slight increase in the risks of death or heart attacks in the DP-DES group after 2 years.

This review assessed the effectiveness and safety of ultra-rapid insulin analogs (URIAs) with continuous subcutaneous insulin systems (CSII) in adults with type 1 diabetes (T1D). The authors concluded that URIAs were compatible with CSII systems and had a better glucose-lowering effect after meals compared to rapid-acting insulin analogs (RAIAs) but may need more infusion set changes.

This study evaluated the effectiveness and safety of ivabradine (Procoralan) in combination with beta-blockers in patients with stable angina. The data showed that the combination of ivabradine plus beta-blocker therapy effectively reduced heart rate, angina symptoms, and the use of short-acting nitrates from the first month of treatment and was safe with manageable side effects in these patients.

This study examined the effects of consuming soymilk and probiotics on risk factors related to heart and blood vessel diseases in patients with type 2 diabetes (T2D). The study showed that the consumption of soymilk with probiotics might improve cardiovascular (CV) risk factors in these patients.

This study evaluated the effect of patient-reported physical and mental health status before revascularization procedures such as percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) on their long-term outcomes in patients with coronary artery disease (CAD). The data showed that patient-reported physical and mental health status before the procedures was strongly associated with long-term mortality in these patients. Patients with the best physical and mental health had better 10-year survival with CABG compared with PCI.

This study compared the safety and effectiveness of different doses of an oral insulin capsule formulation (Capsulin™) to patients with early-stage type 2 diabetes (T2D). The data showed that twice-daily, orally administered Capsulin at a dose of 150 international units (IU) was safe and resulted in a significant lowering of glycated hemoglobin (HbA1c; blood glucose control over the past 2-3 months), fasting plasma glucose (FPG) and triglycerides (TG; blood fats) levels.